Pfizer Inc.
expects demand for its Covid-19 antiviral drug to increase as governments return to replenish their supplies and seek to thwart surges as the pandemic virus continues to evolve.
The treatment, a pill called Paxlovid, brought in $1.5 billion in sales during Pfizer’s first quarter, while its vaccine totaled $13.2 billion, reflecting the need for tools to combat the virus despite a slowdown in cases and a growing sense of life trying to return to normal.
Pfizer’s quarterly sales soared 77% to $25.7 billion, driven by sales of pandemic products, and was higher than analysts expected, according to FactSet.
Pfizer’s strong pandemic sales follow reports last week by
& Co. and
